Eli Lilly Comes to RESI

18 Aug

By Antoinette Lowre, Manager of Business Development, LSN

Eli Lilly joins RESI Boston, September 21-23, providing insight from the large pharma to the RESI community of early-stage players. Eli Lilly is committed to creating high-quality medicines through every aspect of business and the people they serve, stating that “Lilly unites caring with discovery to create medicines that make life better for people around the world.” This is central to Life Science Nation (LSN)’s mission of connecting early-stage life science with capital and channel partners to see healthcare advance. We are thrilled to bring Eli Lilly to RESI to add value to the community and provide new opportunities for investors and founders to gain more exposure to early-stage life science players.

In addition to a Title Sponsorship, Eli Lilly will send a team to source assets within the following sectors and indications:

  1. Genetic Medicine – RNA, Gene-editing, and Gene therapy, including associated delivery technology (e.g. next-gen AAV capsids and non-viral approaches)
  2. Neuroscience, including technology and tools to achieve CNS delivery of therapeutics.
  3. Obesity/Diabetes, including approaches to broaden therapeutic administration routes.

If your product and technology align with these sectors, reach out to us to connect with Eli Lilly at RESI Boston.  Partnering opens soon, so sign up today!

To explore the full breath of Lilly’s interests please visit https://www.lilly.com/partners.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: